All In Biotech

Drug Trial Radar · NCT06405607

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

Psilocybin vs Ketamine for Alcohol Use Disorder

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jun 12, 2025

Primary completion

Apr 2028

Study completion Apr 2028

Sponsor

Lead sponsor
University of IowaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.

Conditions

  • Alcohol Use Disorder
  • Alcohol Dependence
  • Alcohol Abuse

Interventions

  • PsilocybinDrug

    30 mg single dose

  • KetamineDrug

    0.75 mg/kg weight-based single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Timeline Follow-Back for Alcohol to assess changeTime frame: Weekly, over the course of 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.